NCT02753855View on ClinicalTrials.gov

Pharmacokinetics of Telavancin in Normal and Obese Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions

Healthy

Interventions

DRUG

Telavancin

A single dose of telavancin as a 1-hour intravenous infusion

Trial Locations (1)

60612

University of Illinois at Chicago, Chicago

Sponsors

Collaborators (1)

Theravance Biopharma

All Listed Sponsors

collaborator

Theravance Biopharma

INDUSTRY

lead

University of Illinois at Chicago

OTHER